エソメプラゾール
エソメプラゾール 物理性質(zhì)
- 比旋光度 :
- D20 -155° (c = 0.5 in chloroform)
- 沸點 :
- 600.0±60.0 °C(Predicted)
- 比重(密度) :
- 1.37±0.1 g/cm3(Predicted)
- 貯蔵溫度 :
- Sealed in dry,Room Temperature
- 溶解性:
- DMF: 30 mg/ml,DMSO: 20 mg/ml,Ethanol: 10 mg/ml,PBS (pH 7.2): 10 mg/ml
- 外見 :
- A solid
- 酸解離定數(shù)(Pka):
- 8.50±0.10(Predicted)
- 外観:
- 茶色から赤茶色の固體
- Henry's Law Constant:
- 3.3×1013 mol/(m3Pa) at 25℃, HSDB (2015)
- InChI:
- InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m0/s1
- InChIKey:
- SUBDBMMJDZJVOS-DEOSSOPVSA-N
- SMILES:
- C1([S@](CC2=NC=C(C)C(OC)=C2C)=O)NC2=CC(OC)=CC=C2N=1
- CAS データベース:
- 119141-88-7(CAS DataBase Reference)
安全性情報
- リスクと安全性に関する聲明
- 危険有害性情報のコード(GHS)
| 絵表示（GHS） |
|
| 注意喚起語 |
|
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
區(qū)分 |
注意喚起語 |
シンボル |
P コード |
| H312 |
皮膚に接觸すると有害 |
急性毒性、経皮 |
4 |
警告 |
|
P280,P302+P352, P312, P322, P363,P501 |
| H315 |
皮膚刺激 |
皮膚腐食性/刺激性 |
2 |
警告 |
|
P264, P280, P302+P352, P321,P332+P313, P362 |
| H317 |
アレルギー性皮膚反応を起こすおそれ |
感作性、皮膚 |
1 |
警告 |
|
P261, P272, P280, P302+P352,P333+P313, P321, P363, P501 |
| H319 |
強い眼刺激 |
眼に対する重篤な損傷性/眼刺激 性 |
2A |
警告 |
|
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
呼吸器への刺激のおそれ |
特定標(biāo)的臓器毒性、単回暴露； 気道刺激性 |
3 |
警告 |
|
|
|
| 注意書き |
| P264 |
取扱い後は皮膚をよく洗うこと。 |
| P264 |
取扱い後は手や顔をよく洗うこと。 |
| P280 |
保護手袋/保護衣/保護眼鏡/保護面を著用するこ と。 |
| P302+P352 |
皮膚に付著した場合：多量の水と石鹸で洗うこと。 |
| P305+P351+P338 |
眼に入った場合：水で數(shù)分間注意深く洗うこと。次にコ ンタクトレンズを著用していて容易に外せる場合は外す こと。その後も洗浄を続けること。 |
| P312 |
気分が悪い時は醫(yī)師に連絡(luò)すること。 |
| P321 |
特別な処置が必要である（このラベルの．．． を見よ）。 |
| P322 |
特別な処置が必要である（このラベルの．．． を見よ）。 |
| P332 |
皮膚刺激が生じた場合： |
| P363 |
汚染された衣類を再使用す場合には洗濯をすること。 |
| P501 |
內(nèi)容物/容器を．．．に廃棄すること。 |
|
| メーカー |
製品番號 |
製品説明 |
CAS番號 |
包裝 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式會社(wako)
|
W01FLC219545 |
(S)-6-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole |
119141-88-7 |
1g |
￥116900 |
2021-03-23 |
購入 |
|
富士フイルム和光純薬株式會社(wako)
|
W01FLC219545 |
(S)-6-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole |
119141-88-7 |
5g |
￥12500 |
2018-12-26 |
購入 |
|
富士フイルム和光純薬株式會社(wako)
|
W01MAS093119 |
(S)-6-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole |
119141-88-7 |
1g |
￥123400 |
2020-09-21 |
購入 |
|
富士フイルム和光純薬株式會社(wako)
|
W01FLC219545 |
(S)-6-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole |
119141-88-7 |
25g |
￥29700 |
2018-12-26 |
購入 |
|
富士フイルム和光純薬株式會社(wako)
|
W01FLC219545 |
(S)-6-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole |
119141-88-7 |
100g |
￥87800 |
2018-12-26 |
購入 |
エソメプラゾール 化學(xué)特性,用途語,生産方法
効能
胃酸分泌抑制薬, 消化性潰瘍薬, プロトンポンプ阻害薬
説明
Esomeprazole, formulated as a magnesium salt, reached the market as a treatment for
acid-related diseases such as gastro-esophageal reflux (GERD) disease including peptic
ulcer disease and reflux esophagitis. Esomeprazole (formerly perprazole) is the active (S)-
enantiomer of omeprazole (1988) and the first proton pump inhibitor developed as an
optical isomer. It can be obtained by several routes such as asymmetric oxidation of the
pro-chiral pyridylmethyl benzimidazole sulfide, separation from the racemic sulfoxide by
chiral chromatography or separation of a diastereomeric mixture obtained from the racemic
compound and a chiral acid, followed by hydrolysis. Biochemical studies have shown that
esomeprazole irreversibly inhibits the gastric H
+/K
+-adenosine triphosphatase (ATPase),
an enzyme system involved at the secretory surface of the stomach’s parietal cells
responsible for the secretion of gastric acid. Compared with racemic omeprazole in healthy
subjects, esomeprazole has higher bioavailability, is absorbed more rapidly and exhibits a
more uniform and predictable dose-response with higher plasma levels, leading to less
inter-individual variability between slow and rapid metabolizers. In extensive clinical trials
in patients suffering from GERD symptoms, esomeprazole provided superior acid control
and significantly reduced the healing time compared to omeprazole.
使用
(-)-Omeprazole can be used to treat migraine.
使用
Esomeprazole is used to treat certain stomach and esophagus problems (such as acid reflux, ulcers). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as heartburn, difficulty swallowing, and persistent cough.
定義
ChEBI: A 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole that has S configuration at the sulfur atom. An inhibitor of gastric acid secretion, it is used (generally as its sodium or magnesium
alt) for the treatment of gastro-oesophageal reflux disease, dyspepsia, peptic ulcer disease, and Zollinger-Ellison syndrome.
エソメプラゾール 上流と下流の製品情報
原材料
準(zhǔn)備製品
エソメプラゾール 生産企業(yè)
Global( 424)Suppliers
119141-88-7( エソメプラゾール)キーワード:
- 119141-88-7
- EsoMeprazole EC Pellets 22%
- 1H-BenziMidazole,6-Methoxy-2-[(S)-[(4-Methoxy-3,5-diMethyl-2-pyridinyl)Methyl]sulfinyl]-
- EsoMeprazole EC Pellets 8.5%
- 6-Methoxy-2-{(S)-[(4-Methoxy-3,5-diMethyl-2-pyridinyl)Methyl]sulfinyl}-1H-benziMidazole
- Esomeprazole(Na、Mg)
- (5-methoxy-1H-benzimidazol-2-yl)[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfoniumolate
- (S)-Esomeprazole
- Esomeprazole(Mg)
- 5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2- pyridinyl)methyl)sulfinyl)-1H-benzimidazole
- 6-Methoxy-2-[(R)-(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-1H-benzoimidazole
- Esomeprazole
- (RelCpd F)
- (S)-5-Methoxy-2-((4-Methoxy-3,5-diMethylpyridin-2-yl)Methylsulfinyl)-1H-benzo[d]iMidazole
- 119141-58-6
- esomeprazole:5-methoxy-2-((s)-((4-methoxy-3,5-dimethyl-2- pyridinyl)methyl)sulfinyl)-1h-benzIMIDAZOLE
- -6-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)
- Aisi'aomeilazuona Esomeprazole Sodium
- Omeprazole S-Isomer
- Esomeprazol EP Impurity F
- Esomeprzole
- Esomeprazole USP/EP/BP
- Esomeprazole Monomer
- (-)-Omeprazole
- Esomeprazole D3 K salt
- EsomeprazoleQ: What is
Esomeprazole Q: What is the CAS Number of
Esomeprazole
- 5-Methoxy-2-(4-Methoxy-3,5-diMethyl-pyridin-2-ylMethanesulfinyl)-1H-benzoiMidazole
- 5-Methoxy-2-(((4-Methoxy-3,5-diMethylpyridin-2-yl)Methyl)sulfinyl)-1H-benzo[d]iMidazole
- (R)-5-Methoxy-2-(((4-Methoxy-3,5-diMethylpyridin-2-yl)Methyl)sulfinyl)-1H-benzo[d]iMidazole
- (S)-6-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
- ESOMEPRAZOLE 8.5%, 15.0%, 17%, 22%, 22.5%, 27.10% EC PELLETS
- エソメプラゾール
- エソメプラゾール